{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:03:24Z","timestamp":1793189004278,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","funder":[{"name":"Ablative Solutions Inc."}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN have not been formally studied in this indication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded trial investigating the safety and efficacy of alcohol-mediated RDN. Patients with office systolic BP (SBP) \u2265150 and \u2264180 mm\u2009Hg, office diastolic BP \u226590 mm\u2009Hg, and mean 24-hour ambulatory SBP \u2265135 and \u2264170 mm\u2009Hg despite prescription of 2 to 5 antihypertensive medications were enrolled. The primary end point was the baseline-adjusted change in mean 24-hour ambulatory SBP 3 months after the procedure. Secondary end points included mean between-group differences in office and ambulatory BP at additional time points.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              Among 301 patients randomized 1:1 to RDN or sham control, RDN was associated with a significant reduction in 24-hour ambulatory SBP at 3 months (mean\u00b1SD, \u221210.0\u00b114.2 mm\u2009Hg versus \u22126.8\u00b112.1 mm\u2009Hg; treatment difference, \u22123.2 mm\u2009Hg [95% CI, \u22126.3 to 0.0];\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              =0.0487). Subgroup analysis of the primary end point revealed no significant interaction across predefined subgroups. At 3 months, the mean change in office SBP was \u221212.7\u00b118.3 and \u22129.7\u00b117.3 mm\u2009Hg (difference, \u22123.0 [95% CI, \u22127.0 to 1.0];\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              =0.173) for RDN and sham, respectively. No significant differences in ambulatory or office diastolic BP were observed. Adverse safety events through 6 months were uncommon, with one instance of accessory renal artery dissection in the RDN group (0.7%). No significant between-group differences in medication changes or patient adherence were identified.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Alcohol-mediated RDN was associated with a modest but statistically significant reduction in 24-hour ambulatory SBP compared with sham control. No significant differences between groups in office BP or 6-month major adverse events were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>REGISTRATION:<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              ; Unique identifier: NCT02910414.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.124.069291","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:00:23Z","timestamp":1712574023000},"page":"1875-1884","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":59,"title":["Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial"],"prefix":"10.1161","volume":"149","clinical-trial-number":[{"clinical-trial-number":"nct02910414","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David E.","family":"Kandzari","sequence":"first","affiliation":[{"name":"Piedmont Heart Institute, Atlanta, GA (D.E.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-0831","authenticated-orcid":true,"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, State University of New York (SUNY), New York (M.A.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-0096","authenticated-orcid":true,"given":"Atul","family":"Pathak","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Princess Grace Hospital and ESH Hypertension Excellence Center, Monaco (A.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Zidar","sequence":"additional","affiliation":[{"name":"University of North Carolina (UNC), Rex Healthcare, Raleigh, NC (J.P.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-2692","authenticated-orcid":true,"given":"Manish","family":"Saxena","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, Queen Mary University of London, United Kingdom (M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9132-7425","authenticated-orcid":true,"given":"Shukri W.","family":"David","sequence":"additional","affiliation":[{"name":"Ascension Providence Hospital, Southfield, MI (S.W.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5883","authenticated-orcid":true,"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen\/N\u00fcrnberg, Germany (R.E.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Janas","sequence":"additional","affiliation":[{"name":"Collegium Medicum of Andrzej Frycz Modrzewski Krakow University, Krak\u00f3w, Poland (A.J.J.)."},{"name":"Center of Cardiovascular Research and Development, American Heart of Poland, Katowice (A.J.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Langer","sequence":"additional","affiliation":[{"name":"Kardiologisch-Angiologische Praxis, Herzzentrum Bremen, Germany (C.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-9695","authenticated-orcid":true,"given":"Alexandre","family":"Persu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium (A.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrell O","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Cardiology PC, Birmingham, AL (F.O.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Ameloot","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost Limburg, Genk, Belgium (K.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9109-9118","authenticated-orcid":true,"suffix":"III","given":"Malcolm","family":"Foster","sequence":"additional","affiliation":[{"name":"Tennova Turkey Creek Medical Center, Knoxville, TN (M.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim A.","family":"Fischell","sequence":"additional","affiliation":[{"name":"Ablative Solutions Inc, Wakefield, MA (T.A.F.)."},{"name":"Yale University School of Medicine, New Haven, CT (T.A.F., H.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-4973","authenticated-orcid":true,"given":"Helen","family":"Parise","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, CT (T.A.F., H.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":true,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany (F.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","unstructured":"Centers for Disease Control and Prevention. Hypertension cascade: hypertension prevalence treatment and control estimates among US adults aged 18 years and older applying the criteria from the American College of Cardiology and American Heart Association\u2019s 2017 hypertension guideline\u2014NHANES 2017\u20132020. 2023. Accessed March 11 2024. https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence.html"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30752-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00788-1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31082-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30554-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00455-X"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022922"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu441"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.08.045"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00754-7"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.11.041"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2015.04.008"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I1A20"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.10.048"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-23-00088"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.05.015"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/10601331003777444"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2015.08.018"},{"key":"e_1_3_2_21_2","unstructured":"WHO Collaborating Center for Drug Statistics Methodology. ATC Classification Index with DDDs. 2022. Accessed March 11 2024. https:\/\/whocc.no\/use_of_atc_ddd"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19990615)18:11<1341::aid-sim129>3.0.co;2-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.010075"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60308-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835339ac"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30951-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01333-8"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.124.069291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:24:33Z","timestamp":1755523473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.124.069291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,6,11]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.124.069291"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.124.069291","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"2024-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}